SALV Salvarx Group Plc

TIDMSALV

RNS Number : 9194V

SalvaRx Group plc

02 February 2017

SalvaRx Group plc

("SalvaRx" or "the Company")

Intensity Therapeutics Inc.

The Company notes the recent article in MoneyWeek Magazine about SalvaRx and Intensity Therapeutics Inc., ("Intensity") in which the Company has an 8.5 per cent. interest. The article incorrectly stated that Intensity had dosed its first patient in clinical trials. Intensity expects to dose its first patient shortly at which point a further notification will be made by SalvaRx which will contain full details of the trial including the timeframe for results.

 
SalvaRx Group plc 
Ian Walters (Chief Executive)       Tel: +1 203 441 
                                               5451 
 
Northland Capital Partners Limited  Tel: +44 (0) 20 
 Nominated Adviser and Broker             3861 6625 
Matthew Johnson / Edward Hutton 
 (Corporate Finance) 
John Howes (Corporate Broking) 
 
 
Peterhouse Corporate Finance Limited  Tel: +44 (0) 20 
 Joint Broker                               7469 0932 
 Lucy Williams / Duncan Vasey 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAKAAEDKXEFF

(END) Dow Jones Newswires

February 02, 2017 11:37 ET (16:37 GMT)

Salvarx (LSE:SALV)
Historical Stock Chart
From Apr 2024 to May 2024

Salvarx (LSE:SALV)
Historical Stock Chart
From May 2023 to May 2024